Predict your next investment

HEALTHCARE | Biotechnology
cypex.co.uk/intro.htm

See what CB Insights has to offer

Stage

Growth Equity | Alive

Total Raised

$220K

Last Raised

$220K | 23 yrs ago

About Cypex

The patented technology underlying Cypex's products was developed at the University of Dundee during a five-year project in partnership with 15 pharmaceutical companies. The company still maintains close links with the University of Dundee and the industrial members of the consortium involved in the original project. These links are maintained to enable Cypex to remain at the forefront of in vitro drug metabolism technology. The company released its first product in February 2000 and its portfolio has expanded with 22 products covering 11 human cytochrome P450s and 2 drug metabolites. They have also obtained ISO9001 quality accreditation.Cypex's technology claims to enable the expression of human drug metabolising enzymes in bacteria without the need for large modifications to be made to the proteins. These enzymes can be used to conduct tests that provide early assessments of safety profiles for drug toxicity, drug-drug interactions and dosing before a product is introduced in the clinical setting. The tests are performed in vitro, making them cost-effective.Drawing on its expertise in expressing recombinant cytochrome P450s and drug metabolism, Cypex offers contract services both for custom protein expression and the production of drug metabolites.

Cypex Headquarter Location

Gemini Crescent, Technology Park Unit 24, Prospect Business Centre

DD2 1TY,

United Kingdom

44 1382 562391

Latest Cypex News

New insecticide screening platforms indicate that Mitochondrial Complex I inhibitors are susceptible to cross-resistance by mosq...

Oct 1, 2020

Abstract Fenazaquin, pyridaben, tolfenpyrad and fenpyroximate are Complex I inhibitors offering a new mode of action for insecticidal malaria vector control. However, extended exposure to pyrethroid based products such as long-lasting insecticidal nets (LLINs) has created mosquito populations that are largely pyrethroid-resistant, often with elevated levels of P450s that can metabolise and neutralise diverse substrates. To assess cross-resistance liabilities of the Complex I inhibitors, we profiled their susceptibility to metabolism by P450s associated with pyrethroid resistance in Anopheles gambiae (CYPs 6M2, 6P3, 6P4, 6P5, 9J5, 9K1, 6Z2) and An. funestus (CYP6P9a). All compounds were highly susceptible. Transgenic An. gambiae overexpressing CYP6M2 or CYP6P3 showed reduced mortality when exposed to fenpyroximate and tolfenpyrad. Mortality from fenpyroximate was also reduced in pyrethroid-resistant strains of An. gambiae (VK7 2014 and Tiassalé 13) and An. funestus (FUMOZ-R). P450 inhibitor piperonyl butoxide (PBO) significantly enhanced the efficacy of fenpyroximate and tolfenpyrad, fully restoring mortality in fenpyroximate-exposed FUMOZ-R. Overall, results suggest that in vivo and in vitro assays are a useful guide in the development of new vector control products, and that the Complex I inhibitors tested are susceptible to metabolic cross-resistance and may lack efficacy in controlling pyrethroid resistant mosquitoes. Introduction Recent years have seen a plateauing of malaria cases, following halving of malaria fatalities in Africa between 2000–2016. The disease is transmitted to humans by Anopheles mosquitoes and much of this success can be attributed to the use of long-lasting insecticide-treated nets (LLINs) 1 . The mainstay of net insecticides has been members of the pyrethroid class of voltage-gated sodium channel (Vgsc) modulators, due to their rapid knockdown effect against mosquito vectors and low toxicity to humans 2 . The recent small rises in malaria have partly been attributed to pyrethroid resistance evolving rapidly in the major malaria vectors 3 with sixty-six malaria-endemic countries reporting confirmed resistance to this class of insecticide since 2010 4 . The predominant resistance mechanisms to pyrethroid insecticides in malaria vectors are selection of target site insensitivity of the Vgsc, known as knockdown resistance (kdr), and metabolic resistance resulting from increased insecticide detoxification that is most often mediated by cytochromes P450 5 , 6 . Introducing insecticides with alternative modes of action to pyrethroids is critical to mitigate the current resistance issues in mosquito populations 2 . One of the ways to accelerate compounds through to utilisation in public health is through repurposing existing agricultural pesticides for use in appropriate formulations in mosquito control 7 , 8 , 9 . Indeed, a recent screen of 30,000 leads from agriculture chemistries against An. stephensi identified 12 promising chemistries for the control of adult mosquitoes, including complex I inhibitors 10 . Mitochondrial Complex I inhibitors are a structurally diverse group of synthetic insecticides and acaricides that disrupt arthropod respiration by interfering with proton-translocating NADH:ubiquinone oxidoreductase (EC 1.6.5.3; Complex I) activity. This results in the blockade of mitochondrial oxidative phosphorylation and reduced production of ATP (Fig. 1 a) 11 , 12 . Active ingredients from quinazoline (Fenazquin), pyridazinone (Pyridaben) and pyrazole (Fenpyroximate and Tolfenpyrad) groups (Insecticide Resistance Action Committee (IRAC) Mode of Action Class 21A) (Fig. 1 b) are used against agricultural pests and could potentially be used for malaria control. Tolfenpyrad, for instance, has been found effective against Anopheles gambiae, An. arabiensis and Culex quinquefasciatus when used with attractive toxic sugar baits 13 . Recently, all four compounds were included in a screen of pesticides for potential for use against malaria vectors conducted for the Innovative Vector Control Consortium 8 (IVCC) and with the exception of fenazaquin all were shown to be active against An. gambiae exposed via topical application and tarsal contact in the presence of an adjuvant. Tolfenpyrad and fenpyroximate were further shortlisted for consideration as ingredients in new vector control products on the basis of favourable bioefficacy against pyrethroid susceptible An. gambiae 8 . Figure 1 Schematic diagram of the mitochondrial electron transport chain (a) and structures of the Complex I inhibitors used in this study (b). NADH donates two electrons to Complex I (CI), which are transferred to complexes 2–4 (CII–CIV) via quinone (Q) and cytochrome c (Cyt c) co-factors and redox reactions to generate a proton gradient (H+) that drives ATP synthesis. Complex I inhibitors act by disrupting ATP synthesis as a result of the inhibition of NADH:ubiquinone oxidoreductase activity. Given the high levels of pyrethroid resistance in Africa, an important step in the roll-out of alternative chemistries for use against Anopheline populations is to examine their efficacy against pyrethroid resistant mosquitoes and to assess the potential for cross-resistance to pre-existing detoxifying mechanisms in the target populations. Recently, an experimental hut trial was conducted in an area of pyrethroid-resistant An. gambiae s.l., and An. funestus s.s. to identify the efficacy of a non-pyrethroid insecticide-treated durable wall lining (ITWL) 14 . Despite high mortality of pyrethroid resistant strains in lab contact bioassays, a polypropylene material containing abamectin (a macrocyclic lactone targeting chlorine channels) and fenpyroximate demonstrated low efficacy of the ITWL in hut trials which may be attributed to failure of mosquitoes to land on treated surfaces 14 . However potential cross-resistance issues to one of these compounds could not be excluded since they were used as a mixture. Mitochondrial Complex I inhibitors are most commonly used as acaricides and there have been numerous reports of resistance including pyridaben, fenpyroximate and tebufenpyrad in the two-spotted spider mite, Tetranychous urticae 15 , as well as cross-resistance between Complex I inhibitors 16 , 17 , which has been associated with elevated levels of cytochrome P450 (P450 or CYP) activity 17 , 18 . P450s catalyse the mono-oxygenation of a wide range of xenobiotics, which can lead to detoxification of insecticides in arthropods 6 . Many African populations of adult Anopheline mosquitoes express elevated levels of P450 activity associated with metabolic co-resistance to pyrethroids 19 and other insecticide classes. Since P450s can metabolise a wide range of chemical substrates these pose a pre-eminent cross-resistance liability for new chemistries introduced into the insect control market 20 , 21 . An. gambiae CYP6P3 and CYP6M2 and An. funestus CYP6P9a and CYP6P9b are amongst the P450s most commonly found to be overexpressed in pyrethroid-resistant populations and have been demonstrated to metabolise a range of insecticide classes in vitro including pyrethroids, juvenile hormones, organophosphates and carbamates 20 , 21 . Previous work has produced a bank of recombinant P450s commonly overexpressed in pyrethroid-resistant populations of An. gambiae (CYPs 6M2, 6P2, 6P3, 6P4, 6P5, 9J5, 9K1, 6Z2) and An. funestus (CYP6P9a) 21 to screen for metabolic activity in vitro. In addition, the Gal4 UAS system has been used to overexpress CYP6P3 and CYP6M2 22 , 23 in An. gambiae for phenotypic in vivo assessment of P450 metabolism by these key pyrethroid resistance marker genes. Here, we have combined the use of in vitro and transgenic screening, with bioassays on established pyrethroid-resistant strains of An. gambiae and An. funestus with known metabolic resistance markers to assess potential cross-resistance liabilities of Complex I inhibitors. This demonstrated a useful suite of tests that can be applied to other compounds to guide the development of new insecticide-based vector control products. Results In vitro metabolic cross-resistance profile of complex I inhibitors In order to examine the susceptibility of Complex I inhibitors to metabolism by common P450 markers of pyrethroid resistance, fenazaquin, pyridaben, fenpyroximate and tolfenpyrad (Fig. 1 b) were screened against eight An. gambiae P450s (CYPs 6M2, 6P2, 6P3, 6P4, 6P5, 9J5, 9K1, 6Z2) and one An. funestus P450 (CYP6P9a). A substrate depletion assay commonly used for the measurement of drug metabolism was used that is less sensitive than metabolite formation but facilitates rapid screening of multiple compounds. Thus we applied the 20% substrate depletion cut-off value that is normally applied in drug screening to clearly distinguish substrate depletion from weak or uncertain metabolism and baseline variability 24 . Results of this assay are presented in Fig. 2 and Supplementary Table 1 . All four Complex I inhibitors were highly susceptible to metabolism by the P450 panel tested (Fig. 2 and Supplementary Table 1 ). Three compounds, fenazaquin, pyridaben and tolfenpyrad, were metabolised by all P450s in the presence and absence of b5. However, fenpyroximate metabolism was highly dependent on the presence of b5 (Fig. 2 and Supplementary Table 1 ) with all P450s except for CYP6Z2 (28 and 29% depletion in the presence and absence of b5, respectively). Figure 2 Complex I inhibitor metabolism by Anopheles P450s. Bars represent the proportion (% depletion) of 10 μM insecticide cleared by 0.05 µM P450 with (0.4 µM) or without b5 in the presence of NADPH. Values and significance levels are given in Supplementary Table 1 . Error bars represent standard deviation (N = 3). NS, no significant difference in insecticide clearance +/− b5. Complex I and control compounds are indicated. Orange bars, +b5; blue bars, − b5.. In the absence of PBO, FUMOZ-R and VK7 2014 mortality 24 h post-exposure to fenpyroximate were significantly lower than Kisumu (6 ± 4% and 13 ± 4%, respectively vs 73 ± 41%) while the reduction in mortality in Tiassalé 13 (42 ± 50%) was not significant (Fig. 4 ). The results obtained with tolfenpyrad were highly inconsistent. The mortality in Kisumu exposed to tolfenpyrad was not the complete lethality expected with exposure to the LC95 established with this strain in a preliminary experiment (15 ± 15%); the mortality observed was also highly variable between replicates, although significantly higher in Tiassalé 13 (61 ± 46%) and not significantly different between FUMOZ-R (3 ± 3%) or VK7 2014 (8 ± 12%) and Kisumu. In the parallel bioassays performed with bottles coated with the same concentrations of insecticide but with the addition of PBO, despite substantial variation between some replicates, PBO significantly (p < 0.001) enhanced 24-h mortality in all treatments and all strains (Fig. 4 ). Fenpyroximate is a fast-acting insecticide 8 . In many of the treatments in the PBO assay there was some recovery of mosquitoes which were knocked down at the end of exposure but alive 24 h later (Supplementary Table 3 ). Tolfenpyrad was slower acting in comparison, with less than 10% difference in any treatments between knock down and mortality, except for some recovery by 24 h in Kisumu without the addition of PBO. Again, as observed with the transgenic lines, the increase in mortality from 24 to 48 h post-exposure was limited (less than 10% in any treatment, Supplementary Table 3 ). Median mortality in the negative controls, consisting of unexposed and PBO only exposed mosquitoes, was less than 10% over all experiments, and there was no significant increase in mortality (p > 0.05) with the addition of PBO in controls (Supplementary Fig. 1 ). Pyrethroid resistance was confirmed in the three compounds by their significantly lower mortality on exposure to permethrin control bottles than Kisumu (p < 0.05). The addition of PBO to the permethrin controls significantly increased mortality (p < 0.05) in all strains except Kisumu, where mortality in both cases was 100% (Supplementary Table 2 and Supplementary Fig. 1 ), generally consistent with the reported involvement of metabolic mechanisms in the pyrethroid resistance of these strains 28 . Discussion The results presented indicate that many P450s that metabolise pyrethroids also metabolise Complex I inhibitors in the malaria vectors Anopheles gambiae and An. funestus. The highest levels of metabolism were found in the CYP6P family members and CYP6M2, which are most frequently overexpressed across mosquito species endemic in Africa, reinforcing the suggestion that there is broad substrate compatibility of these enzymes and their potential for causing cross-resistance 20 , 21 . More selective metabolism was observed with CYP6Z2, CYP9J5 and CYP9K1; fenazaquin showed susceptibility to CYP6Z2 attack, while pyridaben was susceptible to CYP9J5 and CYP9K1 metabolism. Although the in vitro data is indicative of potential metabolic cross-resistance liabilities, in vivo detoxification that might lead to resistance is dependent on complex physiological factors. These include tissue localisation of P450s and interactions with NADPH-cytochrome P450 reductase (CPR) and b5, which modulate the rate of P450 activity in vitro 31 and in vivo 32 , 33 . Fenpyroximate turnover by nearly all P450s assayed was highly dependent on the presence of b5, which may indicate that this electron transporter partner plays a significant in vivo role in the fenpyroximate resistance observed in the transgenic and wild type mosquitoes. This is further supported by the observation that b5 is commonly found to be upregulated in resistant strains 32 . The transgenic lines offer the possibility to delineate the role individual P450 enzymes play in cross resistance phenotypes, since their genetic background is of susceptible mosquitoes and they overexpress a single P450. Complex I resistance phenotypes were conferred by overexpression of either of the two main insecticide metabolising P450s in An. gambiae. These mosquitoes express the transgene P450s in a broad tissue pattern and at overall levels that are greater than wild type strains 23 . Although not necessarily at physiologically relevant levels, they provide a good indication that these P450s could confer cross-resistance to Complex I inhibitors in pyrethroid resistant wild strains that also express these enzymes at elevated levels. From the transgenic data, it would appear that cyp6M2 has activity against both fenpyroximate and tolfenpyrad, whereas cyp6P3 has reduced activity against the latter compound. In recombinant protein assays both enzymes metabolise fenpyroximate, but only when b5 cofactor is added to the reaction. It may be possible then that the CYP6P3/CPR complex doesn’t associate readily with b5 in vivo, however more research is required to investigate this. The assays in colonised pyrethroid resistant mosquitoes gives a direct indication of the potential for cross resistance to impact mosquito control, but cannot delineate which mechanism may be involved. The Tiassalé 13 and VK7 2014 strains of An. gambiae assayed constitutively overexpress CYP6P3, CYP6P4 and CYP6M2, as well as carry high frequencies of kdr resistance 28 . The VK7 2014 line is also thought to have a cuticular resistance mechanism that also contributes to insecticide resistance. The Anopheles lines also overexpress SAP2, which has recently been shown to confer pyrethroid resistance via a potential sequestration mechanism 34 . In contrast, An. funestus FUMOZ-R overexpresses CYP6P9a and CYP6P9b at up to 70 fold levels above susceptible strains 35 , 36 and do not possess kdr alleles, and thus provide a direct assay of P450 involvement in cross-resistance. As predicted from in vitro and transgenic assays, all strains showed some degree of cross-resistance to fenpyroximate. FUMOZ-R was most highly resistant to fenpyroximate with mortality fully restored (> 98%) by a P450 inhibitor, PBO, as expected from a P450 dominant resistance mechanism. PBO also increased fenpyroximate potency in Tiassalé 13 and VK7 2014, consistent with elevated levels of CYP6P3, CYP6P4 and CYP6M2. However, PBO synergism was not complete, suggesting the potential contribution of other mechanisms described above towards cross-resistance to Complex I inhibitors in these An. gambiae strains. These results echo studies with the agricultural pest species T. urticae , where oxidative metabolism by P450s are clearly involved in Complex I inhibitor cross-resistance, although PBO synergism is not universal and other mechanisms, including target-site resistance are involved 15 , 17 , 37 . The tolfenpyrad results were highly variable using the colonised strains. The control Kisumu strain had far lower mortality (15 ± 15%) than expected in the absence of PBO. This is most likely to be a function of the CDC bottle assays used and the chemical properties of tolfenpyrad (and to a lesser extent using fenpyroximate). At the high concentration of tolfenpyrad used, it seems likely that the compound crystalized under evaporation leading to uneven distribution in the bottle, resulting in lower potency and variability in results. In the presence of PBO, toxicity of tolfenpyrad was restored to the Kisumu strain, which may indicate that mixing of the Complex I inhibitor and PBO alters its surface distribution; PBO may thus act as an adjuvant as well as a synergist in this bioassay. Lower than expected toxicity (87% ± 10) is also observed in the tolfenpyrad bioassays on control transgenic mosquitoes. Although these assays gave consistent results, it should be noted they were performed as tarsal bioassays, where the compounds are dried onto small glass plates and then mosquitoes exposed to the surface with limited space, so forcing interaction with the impregnated surface. Further consideration will be needed to determine the best method to screen future compounds for in vivo efficacy against pyrethroid resistant strains. Conclusions Overall the study highlights the functionality of three compatible screening methods for the liabilities of new compounds to existing resistance mechanisms in mosquitoes. In vitro profiling of fenazaquin, pyridaben, tolfenpyrad and fenpyroximate flagged potential metabolic cross-resistance issues against Anopheles P450s commonly overexpressed in pyrethroid resistant populations of African mosquitoes. This was confirmed for tolfenpyrad and fenpyroximate, where in vivo killing efficacy was significantly reduced against pyrethroid resistant transgenic and laboratory strains of Anopheles. Together, the in vitro and in vivo data suggest that the Complex I inhibitors examined may not be effective for control of pyrethroid resistant mosquitoes due to their metabolic liability. Current trials of LLIN treated with PBO 38 are investigating their potential to enhance the efficacy of conventional insecticides against pyrethroid resistant populations of Anopheles mosquitoes. It is likely that fenpyroximate and tolfenpyrad may also be more effective when used in combination with a P450 inhibitor such as PBO, which merits further investigation. Methods Reagents Diethoxyfluoroscein (DEF) was purchased from Cypex Ltd, UK ( www.cypex.co.uk ). β-Nicotinamide adenine dinucleotide phosphate (NADP+) was purchased from Melford Laboratories Ltd, HPLC solvents from Fisher Scientific UK. Insecticides and all other reagents were supplied by Sigma Aldrich unless indicated otherwise. Insecticide metabolism assays P450 activity is dependent on electrons donated by NADPH via CPR, thus metabolism was assessed by measuring insecticide turnover (percentage substrate depletion) in the presence or absence of NADPH. A cut-off value of 20% substrate depletion was used to distinguish turnover from baseline variability 24 . Reactions were also carried out in the presence and absence of cytochrome b5 (b5), which is located with P450 and CPR in the endoplasmic reticulum and can modify catalysis depending on the substrate and P450 involved 39 . Deltamethrin and DDT were included as comparative positive and negative controls, respectively, for P450 metabolism. Since this was designed as a rapid screen, the enzyme reactions were carried out using a single long time point of 2 h to detect a broad range of metabolic efficiency. E. coli membranes co-expressing P450 and An. gambiae NADPH cytochrome P450 oxidoreductase (AgCPR) were supplied by Cypex Ltd, UK ( www.cypex.co.uk ). P450s were expressed using pCWori + expression vector constructs as described previously for CYPs 6M2 and 6P3, 6P4, 6P5, 9J5 20 , CYP6Z2 26 , CYP6P9a 21 and CYP9K1 25 . An. gambiae cytochrome b5 (b5) supplied by Cypex Ltd, UK was prepared as described previously to supplement enzyme reactions at a 8:1 molar ratio, b5:P450 40 . Reactions were carried out in vitro using a NADPH-regenerating system in triplicate in the presence and absence of NADP + . Insecticides were prepared as a working stock in ethanol and stored at − 20 °C; solvent content was 2% of the final reaction. A reaction volume of 100 µl contained 0.05 µM CYP450, 0.4 µM b5 (absent in − b5 reactions), 10 μM compound and 50 mM potassium phosphate buffer (KPB) at pH 7.4. The regenerating mix included 1 mM glucose-6-phosphate, 0.25 mM MgCl2, 0.1 mM NAPD + (absent –NADPH) and 1 unit/ml glucose-6-phosphate dehydrogenase (G6PDH). Reactions were pre-incubated at 30 °C for 5 min and started by adding the NADPH-regenerating mix, the reactions continued at 30 °C for 2 h, shaking at 1200 rpm and quenched with 100 µl acetonitrile. Samples were centrifuged at 16,000 g for 20 min, before 150 µl of the supernatant was used for HPLC. Results were calculated as percentage depletion of the insecticide peak area in the presence of NADPH (+NADPH) versus absence of NADPH (−NADPH) to give a quantitative assessment of metabolism. High-performance liquid chromatography (HPLC) analysis Samples were analysed using a C18 Reverse-Phase LC Hypersil Gold Column, Thermofisher Scientific, on an Agilent 1100 series HPLC or Dionex UltiMate 3000 at 23 °C. 100 µl of organic solvent-quenched reaction supernatant was injected onto the column with isocratic mobile phases of 80% acetonitrile and 20% water with 0.1% phosphoric acid for fenpyroximate, pyridaben, tolfenpyrad, fenazaquin and deltamethrin, and 85% methanol and 15% water for DDT. Flow rates were 1 ml/min and monitoring absorbance wavelength was 226 nm apart from DDT, which was 232 nm. Elution times for the insecticides were as follows: fenpyroximate, 7.7 min; tolfenpyrad, 6.0 min; fenazaquin, 7.9 min; pyridaben, 9.3 min; deltamethrin, 9.8 min and DDT, 10.8 min. The insecticide was quantified by peak integration (OpenLAB Chromatography Data System). Examples of chromatograms used for peak quantification and quantitative assessment of P450 metabolism are illustrated in Supplementary Fig. 2 . Rearing mosquitoes for bioassays All bioassays were carried out on 2–5 day old non-blood-fed female mosquitoes, reared at the Liverpool School of Tropical Medicine (LSTM), in insectaries maintained at 26 °C ± 2 °C and 80% relative humidity ± 10% with a L12:D12 hour light:dark cycle and 1 h dawn and dusk 28 . Ground Tetramin tropical fish food flakes (Tetra, Blacksburg, VA, USA) was used as a larval diet, adults were provided with a 10% sucrose solution. For egg production, adult females adults were fed on 50:50 mixture of research red cells and plasma supplied by NHS Blood and Transplant, UK. For the bioassays of P450 overexpressing mosquitoes, crosses were established between the homozygous ubiquitous Gal4 driver line Ubi-A10 22 , fluorescently tagged with CFP, and the homozygous responder lines UAS-Cyp6p3 and Cyp6m2, marked with yellow fluorescent protein 23 or with wild type G3 mosquitoes (non-fluorescent). Pupal progeny were screened to confirm inheritance of correct markers and allowed to hatch into adults. Tarsal bioassays on transgenic mosquitoes A glass plate tarsal contact assay described previously 8 was used to expose transgenic adult females, alongside driver line/+ controls to 125 mg/m2 of each insecticide and 100 mg/m2 of the adjuvant RME (Mero, Bayer, Reading, UK: 81.4% w/w rapeseed fatty acid esters and emulsifier ethoxy (7) tridecanol) applied in acetone to glass Petri dishes (radius 2.5 cm, SLS, Nottingham, UK) for 30 min. Mosquitoes were then aspirated into holding cups and scored immediately for knock down, provided with 10% sugar solution on cotton wool and held at 27 ± 2 °C 70 ± 10% relative humidity 12:12 h light:dark cycle to be scored for mortality 24 and 48 h (± 2 h) after the end of exposure. Ten mosquitoes were exposed per glass plate, and 6 replicates were completed per treatment per strain. PBO assay Three strains of Anopheles gambiae, Kisumu, Tiassalé 13 and VK7 2014, and one strain of Anopheles funestus, FUMOZ-R, were used for the in vivo PBO assays. Colonies were established, characterised and maintained as described by Williams et al. 28 . The inside of 250 ml Wheaton bottles were coated according to the CDC ‘Guideline for Evaluating Insecticide Resistance in Vectors Using the CDC Bottle Bioassay’ 29 with 1.6 ml of solutions comprising insecticides dissolved in acetone plus the adjuvant RME, both with and without PBO, with 2 negative controls (acetone and RME, and acetone, RME and PBO) and 2 positive controls (20 µg/bottle permethrin, with and without PBO). The concentration of each test insecticide was the LC95 calculated from the results of dose response experiments with the Kisumu susceptible strain 8 : 160.8 µg/bottle Fenpyroximate and 143.84 µg/bottle Tolfenpyrad. A concentration of 400 µg/bottle PBO was used as it is recommended by the CDC for synergist bioassays 41 . Three replicate bottles were coated and tested per treatment for each of the four strains. Bioassays were conducted in controlled conditions: 27 ± 2 °C 70 ± 10% relative humidity. Twenty five 2–5 day old adult female mosquitoes, allowed to mate but not blood feed, were added to each bottle and left for a 60 min exposure period. Mosquitoes were then aspirated into holding cups and scored immediately for knock down, provided with 10% sugar solution on cotton wool and held at 27 ± 2 °C 70 ± 10% relative humidity 12:12 h light:dark cycle to be scored for mortality 24 and 48 h (± 2 h) after the end of exposure. Three replicate bioassays were carried out per strain, each with a different set of bottles coated no more than 24 h previously. Knock down was scored immediately after the one hour exposure and mortality was scored 24 and 48 h post-exposure as defined by the World Health Organisation (‘immobile or unable to stand or take off’) 28 . Data analysis In the transgenic assays mean mortality 24 h post-exposure was calculated from all replicates of a treatment, reported ± 95% confidence intervals. Where 95% CI for a strain overexpressing a P450 did not overlap with the mean mortality in the control group the effect of P450 overexpression on insecticide sensitivity was deemed to be significant. In the PBO assay, to detect cross resistance in the pyrethroid resistant strains, mean mortality 24 h post-exposure was calculated from all replicates of a treatment, reported ± 95% confidence intervals. Where 95% CI for a resistant strain did not overlap with the mean mortality for Kisumu the level of cross resistance was deemed to be significant. The effect of PBO on 24-h mortality for each compound was assessed, and pairwise comparisons made between observations at different time points, using a 1 tailed Fisher’s Exact test to determine where synergism was significant (p < 0.001). Data availability References 1. Bhatt, S. et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature 526, 1–9 (2015). Supplementary information Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ .

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.